priors.science/reviews/targeted-therapy-prostate-cancer

Targeted Therapy Prostate Cancer

The current evidence on 17 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

17claims tracked
245primary papers reviewed
10 Aug 2026latest evidence review
Weeklyre-scored against new papers
10 Established · 6 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Abiraterone overall survival benefit in metastatic hormone-sensitive prostate cancerAdt IntensifyEstablished90%19
Enzalutamide overall survival benefit in metastatic castration-resistant prostate cancerArpiEstablished89%16
Enzalutamide metastasis-free survival benefit in non-metastatic castration-resistant prostate cancerNmcrpcEstablished89%16
Abiraterone overall survival benefit post-docetaxel in metastatic castration-resistant prostate cancerArpiEstablished88%20
Lu-PSMA-617 overall survival in metastatic castration-resistant prostate cancer (VISION)PsmaEstablished88%20
Radium-223 overall survival in bone-only metastatic castration-resistant prostate cancerBoneEstablished87%20
Overall survival benefit of androgen receptor inhibitors in non-metastatic castration-resistant prostate cancerNmcrpcEstablished87%17
Olaparib radiographic progression-free survival in homologous recombination repair-mutant metastatic castration-resistant prostate cancerPARPEstablished87%15
PSMA PET staging superior to conventional imagingPsmaEstablished86%17
Enzalutamide or darolutamide overall survival in metastatic hormone-sensitive prostate cancerAdt IntensifyLikely75%20
PARP plus androgen receptor inhibitor combination in metastatic castration-resistant prostate cancerPARPLikely74%14
Androgen receptor splice variant 7 predicts androgen receptor inhibitor resistanceResistanceLong-standingLikely73%17
Pembrolizumab activity in microsatellite instability-high or high tumour mutational burden prostate cancerResistanceLikely72%16
PTEN loss and androgen receptor inhibitor resistance in metastatic castration-resistant prostate cancerResistanceLikely71%18
Androgen receptor inhibitor sequence cross-resistanceArpiLong-standingLikely70%19
Rucaparib benefit in non-BRCA homologous recombination repair metastatic castration-resistant prostate cancerPARPUncertain58%18
Track Targeted Therapy Prostate Cancer.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.